Trials / Terminated
TerminatedNCT03120676
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study with the purpose of studying the safety and efficacy of the study drug Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab could shrink cancer but it could also cause side effects. This study will also test any good and bad effects the study drug. Other aims include studying biomarkers that will help researchers understand how the drug works.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle. |
Timeline
- Start date
- 2017-04-14
- Primary completion
- 2018-11-12
- Completion
- 2018-11-12
- First posted
- 2017-04-19
- Last updated
- 2019-11-14
- Results posted
- 2019-11-14
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03120676. Inclusion in this directory is not an endorsement.